PI3K inhibitors in inflammation, autoimmunity and cancer

Current Opinion in Pharmacology

Volumn 23, Issue , 2015, Pages 82-91

  Stark, Anne Katrien ^a   Sriskantharajah, Srividya ^b   Hessel, Edith M ^b   Okkenhaug, Klaus ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 5 (9 ISOPROPYL 8 METHYL 2 MORPHOLINO 9H PURIN 6 YL) 2 PYRIMIDINAMINE; 8 (6 METHOXY 3 PYRIDINYL) 3 METHYL 1 [4 (1 PIPERAZINYL) 3 (TRIFLUOROMETHYL)PHENYL] 1H IMIDAZO[4,5 C]QUINOLIN 2(3H) ONE; ACALISIB; ALPELISIB; AMG 319; AQX 1125; AZD 8186; BUPARLISIB; COPANLISIB; CZC 24823; DACTOLISIB; DUVELISIB; GSK 2269557; IDELALISIB; MAMMALIAN TARGET OF RAPAMYCIN; MLN 1117; OMIPALISIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROTEIN KINASE B; RP 6530; RV 1729; SONOLISIB; TASP 0415914; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOXTALISIB; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ENZYME INHIBITOR;

ADVANCED CANCER; ARTHRITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AUTOPHAGY; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INTERSTITIAL CYSTITIS; KIDNEY CANCER; LUNG CANCER; LUNG FIBROSIS; LYMPHOCYTOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MULTIPLE SCLEROSIS; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FOLDING; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; INFLAMMATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84935890863     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.05.017     Document Type: Review

References (81)

1. P.T. Hawkins, and L.R. Stephens PI3K signalling in inflammation Biochim Biophys Acta 1851 2015 882 897
2. K. Okkenhaug Signaling by the phosphoinositide 3-kinase family in immune cells Annu Rev Immunol 31 2013 675 704
3. J.G. Foster, M.D. Blunt, E. Carter, and S.G. Ward Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies Pharmacol Rev 64 2012 1027 1054
4. M.C. Schmid, C.J. Avraamides, H.C. Dippold, I. Franco, P. Foubert, L.G. Ellies, L.M. Acevedo, J.R. Manglicmot, X. Song, and W. Wrasidlo Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression Cancer Cell 19 2011 715 727
5. D.A. Fruman, and C. Rommel PI3K and cancer: lessons, challenges and opportunities Nat Rev Drug Discov 13 2014 140 156
6. F. Ramadani, D.J. Bolland, F. Garcon, J.L. Emery, B. Vanhaesebroeck, A.E. Corcoran, and K. Okkenhaug The PI3K isoforms p110 alpha and p110 delta are essential for pre-B cell receptor signaling and B cell development Sci Signal 3 2010
7. S. Kulkarni, C. Sitaru, Z. Jakus, K.E. Anderson, G. Damoulakis, K. Davidson, M. Hirose, J. Juss, D. Oxley, and T.A. Chessa PI3Kbeta plays a critical role in neutrophil activation by immune complexes Sci Signal 4 2011 ra23
8. Y. Leverrier, K. Okkenhaug, C. Sawyer, A. Bilancio, B. Vanhaesebroeck, and A.J. Ridley Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages J Biol Chem 278 2003 38437 38442
9. D.R. Soond, E. Bjorgo, K. Moltu, V.Q. Dale, D.T. Patton, K.M. Torgersen, F. Galleway, B. Twomey, J. Clark, and J.S. Gaston PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans Blood 115 2010 2203 2213
10. D.T. Patton, J.L. Emery, W.C. Rowan, and K. Okkenhaug PI3K p110 delta controls the differentiation and function of regulatory T cells Immunology 125 2008 129
11. D.T. Patton, M.D. Wilson, W.C. Rowan, D.R. Soond, and K. Okkenhaug The PI3K p110 delta regulates expression of CD38 on regulatory T cells PLoS ONE 6 2011
12. A.M. Condliffe, K. Davidson, K.E. Anderson, C.D. Ellson, T. Crabbe, K. Okkenhaug, B. Vanhaesebroeck, M. Turner, L. Webb, and M.P. Wymann Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils Blood 106 2005 1432 1440
13. E. Sapey, H. Greenwood, G. Walton, E. Mann, A. Love, N. Aaronson, R.H. Insall, R.A. Stockley, and J.M. Lord Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence Blood 123 2014 239 248
14. M. Laffargue, R. Calvez, P. Finan, A. Trifilieff, M. Barbier, F. Altruda, E. Hirsch, and M.P. Wymann Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function Immunity 16 2002 441 451
15. E. Collmann, T. Bohnacker, R. Marone, J. Dawson, M. Rehberg, R. Stringer, F. Krombach, C. Burkhart, E. Hirsch, and G.J. Hollingworth Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy J Allergy Clin Immunol 132 2013 959 968
16. K. Ali, M. Camps, W.P. Pearce, H. Ji, T. Ruckle, N. Kuehn, C. Pasquali, C. Chabert, C. Rommel, and B. Vanhaesebroeck Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo J Immunol 180 2008 2538 2544
17. E.A. Papakonstanti, O. Zwaenepoel, A. Bilancio, E. Burns, G.E. Nock, B. Houseman, K. Shokat, A.J. Ridley, and B. Vanhaesebroeck Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages J Cell Sci 121 2008 4124 4133
18. C. Koorella, J.R. Nair, M.E. Murray, L.M. Carlson, S.K. Watkins, and K.P. Lee Novel regulation of CD80/CD86-induced phosphatidylinositol 3-kinase signaling by NOTCH1 protein in interleukin-6 and indoleamine 2,3-dioxygenase production by dendritic cells J Biol Chem 289 2014 7747 7762
19. M.H. Laird, S.H. Rhee, D.J. Perkins, A.E. Medvedev, W. Piao, M.J. Fenton, and S.N. Vogel TLR4/MyD88/PI3K interactions regulate TLR4 signaling J Leukoc Biol 85 2009 966 977
20. M.P. Fallah, R.L. Chelvarajan, B.A. Garvy, and S. Bondada Role of phosphoinositide 3-kinase-Akt signaling pathway in the age-related cytokine dysregulation in splenic macrophages stimulated via TLR-2 or TLR-4 receptors Mech Ageing Dev 132 2011 274 286
21. E. Aksoy, S. Taboubi, D. Torres, S. Delbauve, A. Hachani, M.A. Whitehead, W.P. Pearce, I.M. Berenjeno, G. Nock, and A. Filloux The p110delta isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock Nat Immunol 13 2012 1045 1054
22. W. Bai, H. Liu, Q. Ji, Y. Zhou, L. Liang, R. Zheng, J. Chen, Z. Liu, H. Yang, and P. Zhang TLR3 regulates mycobacterial RNA-induced IL-10 production through the PI3K/AKT signaling pathway Cell Signal 26 2014 942 950
23. J. Brown, H. Wang, G.N. Hajishengallis, and M. Martin TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk J Dent Res 90 2011 417 427
24. W. Fan, H. Morinaga, J.J. Kim, E. Bae, N.J. Spann, S. Heinz, C.K. Glass, and J.M. Olefsky FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages EMBO J 29 2010 4223 4236
25. C. Guiducci, C. Ghirelli, M.A. Marloie-Provost, T. Matray, R.L. Coffman, Y.J. Liu, F.J. Barrat, and V. Soumelis PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation J Exp Med 205 2008 315 322
26. G. Schabbauer, U. Matt, P. Gunzl, J. Warszawska, T. Furtner, E. Hainzl, I. Elbau, I. Mesteri, B. Doninger, and B.R. Binder Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia J Immunol 185 2010 468 476
27. E. Banham-Hall, M.R. Clatworthy, and K. Okkenhaug The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases Open Rheumatol J 6 2012 245 258
28. S. Sriskantharajah, N. Hamblin, S. Worsley, A.R. Calver, E.M. Hessel, and A. Amour Targeting phosphoinositide 3-kinase delta for the treatment of respiratory diseases Ann N Y Acad Sci 1280 2013 35 39
29. J. Doukas, L. Eide, K. Stebbins, A. Racanelli-Layton, L. Dellamary, M. Martin, E. Dneprovskaia, G. Noronha, R. Soll, and W. Wrasidlo Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease J Pharmacol Exp Ther 328 2009 758 765
30. D.G. Winkler, K.L. Faia, J.P. DiNitto, J.A. Ali, K.F. White, E.E. Brophy, M.M. Pink, J.L. Proctor, J. Lussier, and C.M. Martin PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models Chem Biol 20 2013 1364 1374
31. J.A. Marwick, G. Caramori, C.S. Stevenson, P. Casolari, E. Jazrawi, P.J. Barnes, K. Ito, I.M. Adcock, P.A. Kirkham, and A. Papi Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice Am J Respir Crit Care Med 179 2009 542 548
32. S.J. Park, K.S. Lee, S.R. Kim, K.H. Min, H. Moon, M.H. Lee, C.R. Chung, H.J. Han, K.D. Puri, and Y.C. Lee Phosphoinositide 3-kinase delta inhibitor suppresses interleukin-17 expression in a murine asthma model Eur Respir J 36 2010 1448 1459
33. B.F. Nashed, T. Zhang, M. Al-Alwan, G. Srinivasan, A.J. Halayko, K. Okkenhaug, B. Vanhaesebroeck, K.T. Hayglass, and A.J. Marshall Role of the phosphoinositide 3-kinase p110delta in generation of type 2 cytokine responses and allergic airway inflammation Eur J Immunol 37 2007 416 424
34. J.A. Marwick, K.F. Chung, and I.M. Adcock Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease Ther Adv Respir Dis 4 2010 19 34
35. E. Sapey, J.A. Stockley, H. Greenwood, A. Ahmad, D. Bayley, J.M. Lord, R.H. Insall, and R.A. Stockley Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 183 2011 1176 1186
36. J.K. Juss, R.P. Hayhoe, C.E. Owen, I. Bruce, S.R. Walmsley, A.S. Cowburn, S. Kulkarni, K.B. Boyle, L. Stephens, and P.T. Hawkins Functional redundancy of class I phosphoinositide 3-kinase (PI3K) isoforms in signaling growth factor-mediated human neutrophil survival PLOS ONE 7 2012 e45933
37. M. El-Behi, B. Ciric, H. Dai, Y. Yan, M. Cullimore, F. Safavi, G.X. Zhang, B.N. Dittel, and A. Rostami The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF Nat Immunol 12 2011 568 575
38. H. Li, D. Park, P.M. Abdul-Muneer, B. Xu, H. Wang, B. Xing, D. Wu, and S. Li PI3Kgamma inhibition alleviates symptoms and increases axon number in experimental autoimmune encephalomyelitis mice Neuroscience 253 2013 89 99
39. L. Berod, C. Heinemann, S. Heink, A. Escher, C. Stadelmann, S. Drube, R. Wetzker, J. Norgauer, and T. Kamradt PI3Kgamma deficiency delays the onset of experimental autoimmune encephalomyelitis and ameliorates its clinical outcome Eur J Immunol 41 2011 833 844
40. S. Haylock-Jacobs, I. Comerford, M. Bunting, E. Kara, S. Townley, M. Klingler-Hoffmann, B. Vanhaesebroeck, K.D. Puri, and S.R. McColl PI3Kdelta drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation J Autoimmun 36 2011 278 287
41. K. Ali, D.R. Soond, R. Pineiro, T. Hagemann, W. Pearce, E.L. Lim, H. Bouabe, C.L. Scudamore, T. Hancox, and H. Maecker Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer Nature 510 2014 407 411
42. E. Sahin, S. Haubenwallner, M. Kuttke, I. Kollmann, A. Halfmann, A.B. Dohnal, L. Chen, P. Cheng, B. Hoesel, and E. Einwallner Macrophage PTEN regulates expression and secretion of arginase I modulating innate and adaptive immune responses J Immunol 193 2014 1717 1727
43. A. Roller, A. Perino, P. Dapavo, E. Soro, K. Okkenhaug, E. Hirsch, and H. Ji Blockade of phosphatidylinositol 3-kinase (PI3K)delta or PI3K gamma reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis J Immunol 189 2012 4612 4620
44. H. Ying, H. Fu, M.L. Rose, A.M. McCormack, P. Sarathchandra, K. Okkenhaug, and F.M. Marelli-Berg Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110delta prevents chronic rejection of heart allografts PLOS ONE 7 2012 e32892
45. C.A. Durand, M.J. Richer, K. Brenker, M. Graves, I. Shanina, K. Choi, M.S. Horwitz, K.D. Puri, and M.R. Gold Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice Autoimmunity 46 2013 62 73
46. Y. Wang, L. Zhang, P. Wei, H. Zhang, and C. Liu Inhibition of PI3Kdelta improves systemic lupus in mice Inflammation 37 2014 978 983
47. D.F. Barber, A. Bartolome, C. Hernandez, J.M. Flores, C. Redondo, C. Fernandez-Arias, M. Camps, T. Ruckle, M.K. Schwarz, and S. Rodriguez PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus Nat Med 11 2005 933 935
48. A. Suarez-Fueyo, J.M. Rojas, A.E. Cariaga, E. Garcia, B.H. Steiner, D.F. Barber, K.D. Puri, and A.C. Carrera Inhibition of PI3Kdelta reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse J Immunol 193 2014 544 554
49. P. Haselmayer, M. Camps, M. Muzerelle, S. El Bawab, C. Waltzinger, L. Bruns, N. Abla, M.A. Polokoff, C. Jond-Necand, and M. Gaudet Characterization of novel PI3Kdelta inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies Front Immunol 5 2014 233
50. M.J. Maxwell, E. Tsantikos, A.M. Kong, B. Vanhaesebroeck, D.M. Tarlinton, and M.L. Hibbs Attenuation of phosphoinositide 3-kinase delta signaling restrains autoimmune disease J Autoimmun 38 2012 381 391
51. Y. Oka, T. Yabuuchi, T. Oi, S. Kuroda, Y. Fujii, H. Ohtake, T. Inoue, S. Wakahara, K. Kimura, and K. Fujita Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase gamma inhibitor for the treatment of inflammatory diseases Bioorg Med Chem 21 2013 7578 7583
52. M. Camps, T. Ruckle, H. Ji, V. Ardissone, F. Rintelen, J. Shaw, C. Ferrandi, C. Chabert, C. Gillieron, and B. Francon Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis Nat Med 11 2005 936 943
53. T.M. Randis, K.D. Puri, H. Zhou, and T.G. Diacovo Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils Eur J Immunol 38 2008 1215 1224
54. K. Haruta, S. Mori, N. Tamura, A. Sasaki, M. Nagamine, S. Yaguchi, F. Kamachi, J. Enami, S. Kobayashi, and T. Yamori Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats Inflamm Res 61 2012 551 562
55. Z. Xue, W. Li, H. Wang, B. Huang, Z. Ge, C. Gu, Y. Liu, K. Zhang, J. Yang, and R. Han ZSTK474, a novel PI3K inhibitor, modulates human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis J Mol Med (Berl) 92 2014 1057 1068
56. M. Martini, E. Ciraolo, F. Gulluni, and E. Hirsch Targeting PI3K in cancer: any good news? Front Oncol 3 2013 108
57. O. Williams, B.T. Houseman, E.J. Kunkel, B. Aizenstein, R. Hoffman, Z.A. Knight, and K.M. Shokat Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs Chem Biol 17 2010 123 134
58. U.A. Maus, M. Backi, C. Winter, M. Srivastava, M.K. Schwarz, T. Ruckle, J.C. Paton, D. Briles, M. Mack, and T. Welte Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection Am J Respir Crit Care Med 175 2007 958 966
59. R.R. Furman, J.P. Sharman, S.E. Coutre, B.D. Cheson, J.M. Pagel, P. Hillmen, J.C. Barrientos, A.D. Zelenetz, T.J. Kipps, and I. Flinn Idelalisib and rituximab in relapsed chronic lymphocytic leukemia N Engl J Med 370 2014 997 1007
60. B.W. Miller, D. Przepiorka, R.A. de Claro, K. Lee, L. Nie, N. Simpson, R. Gudi, H. Saber, S. Shord, and J. Bullock FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma Clin Cancer Res 21 2015 1525 1529
61. K. Okkenhaug, A. Bilancio, G. Farjot, H. Priddle, S. Sancho, E. Peskett, W. Pearce, S.E. Meek, A. Salpekar, and M.D. Waterfield Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice Science 297 2002 1031 1034
62. I. Angulo, O. Vadas, F. Garcon, E. Banham-Hall, V. Plagnol, T.R. Leahy, H. Baxendale, T. Coulter, J. Curtis, and C. Wu Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage Science 342 2013 866 871
63. C.L. Lucas, H.S. Kuehn, F. Zhao, J.E. Niemela, E.K. Deenick, U. Palendira, D.T. Avery, L. Moens, J.L. Cannons, and M. Biancalana Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency Nat Immunol 15 2014 88 97
64. M.C. Crank, J.K. Grossman, S. Moir, S. Pittaluga, C.M. Buckner, L. Kardava, A. Agharahimi, H. Meuwissen, J. Stoddard, and J. Niemela Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility J Clin Immunol 34 2014 272 276
65. S. Kracker, J. Curtis, M.A. Ibrahim, A. Sediva, J. Salisbury, V. Campr, M. Debre, J.D. Edgar, K. Imai, and C. Picard Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase delta syndrome J Allergy Clin Immunol 134 2014 233 236
66. M.C. Deau, L. Heurtier, P. Frange, F. Suarez, C. Bole-Feysot, P. Nitschke, M. Cavazzana, C. Picard, A. Durandy, and A. Fischer A human immunodeficiency caused by mutations in the PIK3R1 gene J Clin Invest 124 2014 3923 3928
67. C.L. Lucas, Y. Zhang, A. Venida, Y. Wang, J. Hughes, J. McElwee, M. Butrick, H. Matthews, S. Price, and M. Biancalana Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K J Exp Med 211 2014 2537 2547
68. L.M. Thorpe, H. Yuzugullu, and J.J. Zhao PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting Nat Rev Cancer 15 2014 7 24
69. A.K. Gopal, B.S. Kahl, S. de Vos, N.D. Wagner-Johnston, S.J. Schuster, W.J. Jurczak, I.W. Flinn, C.R. Flowers, P. Martin, and A. Viardot PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma N Engl J Med 370 2014 1008 1018
70. J.M. Doisne, C.M. Huber, K. Okkenhaug, and F. Colucci Immunomodulation of selective naive T cell functions by p110delta inactivation improves the outcome of mismatched cell transplantation Cell Rep 10 2015 702 710
71. T. Maffucci, and M. Falasca New insight into the intracellular roles of class II phosphoinositide 3-kinases Biochem Soc Trans 42 2014 1378 1382
72. J.M. Backer The regulation and function of Class III PI3Ks: novel roles for Vps34 Biochem J 410 2008 1 17
73. V.V. Parekh, L. Wu, K.L. Boyd, J.A. Williams, J.A. Gaddy, D. Olivares-Villagomez, T.L. Cover, W.X. Zong, J. Zhang, and L. Van Kaer Impaired autophagy, defective T cell homeostasis, and a wasting syndrome in mice with a T cell-specific deletion of Vps34 J Immunol 190 2013 5086 5101
74. B. Ronan, O. Flamand, L. Vescovi, C. Dureuil, L. Durand, F. Fassy, M.F. Bachelot, A. Lamberton, M. Mathieu, and T. Bertrand A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy Nat Chem Biol 10 2014 1013 1019
75. W.E. Dowdle, B. Nyfeler, J. Nagel, R.A. Elling, S. Liu, E. Triantafellow, S. Menon, Z. Wang, A. Honda, and G. Pardee Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo Nat Cell Biol 16 2014 1069 1079
76. R. Bago, N. Malik, M.J. Munson, A.R. Prescott, P. Davies, E. Sommer, N. Shpiro, R. Ward, D. Cross, and I.G. Ganley Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase Biochem J 463 2014 413 427
77. T. Marsh, and J. Debnath Ironing out VPS34 inhibition Nat Cell Biol 17 2014 1 3
78. N. Jaber, Z. Dou, J.S. Chen, J. Catanzaro, Y.P. Jiang, L.M. Ballou, E. Selinger, X. Ouyang, R.Z. Lin, and J. Zhang Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function Proc Natl Acad Sci U S A 109 2012 2003 2008
79. R.P. Shugg, A. Thomson, N. Tanabe, A. Kashishian, B.H. Steiner, K.D. Puri, A. Pereverzev, B.J. Lannutti, F.R. Jirik, and S.J. Dixon Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption J Biol Chem 288 2013 35346 35357
80. G. Bergamini, K. Bell, S. Shimamura, T. Werner, A. Cansfield, K. Muller, J. Perrin, C. Rau, K. Ellard, and C. Hopf A selective inhibitor reveals PI3Kgamma dependence of T(H)17 cell differentiation Nat Chem Biol 8 2012 576 582
81. J. Doukas, W. Wrasidlo, G. Noronha, E. Dneprovskaia, R. Fine, S. Weis, J. Hood, A. Demaria, R. Soll, and D. Cheresh Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury Proc Natl Acad Sci U S A 103 2006 19866 19871